Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues

Patient-derived tumor xenograft models represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture; however, their use is low-throughput and costly. To overcome this limitation, patient-derived tumor organoids (PDOs) were established from hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Hirosumi, Higa, Arisa, Hoshi, Hirotaka, Hiyama, Gen, Takahashi, Nobuhiko, Ryufuku, Masae, Morisawa, Gaku, Yanagisawa, Yuka, Ito, Emi, Imai, Jun-Ichi, Dobashi, Yuu, Katahira, Kiyoaki, Soeda, Shu, Watanabe, Takafumi, Fujimori, Keiya, Watanabe, Shinya, Takagi, Motoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072291/
https://www.ncbi.nlm.nih.gov/pubmed/29917168
http://dx.doi.org/10.3892/or.2018.6501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072291/
https://www.ncbi.nlm.nih.gov/pubmed/29917168
http://dx.doi.org/10.3892/or.2018.6501

Ejemplares similares